14 results
424B5
TPST
Tempest Therapeutics Inc
20 Jun 24
Prospectus supplement for primary offering
8:32am
to the amezalpat arm and 30 patients randomized to the control arm.
Key Updates:
Strong Median Overall Survival Improvement and Maintenance of Hazard Ratio … observed in the standard-of-care arm of atezolizumab plus bevacizumab. Importantly, the amezalpat arm also maintained its hazard ratio, or HR
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier
Early and persistent separation of survival curves
OS … . “These new data come after 10 more months of follow-up since the last data analysis and show not only a strong hazard ratio of 0.65 favoring
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
19 Mar 24
Tempest Reports Year End 2023 Financial Results and Provides Business Update
4:10pm
), as compared to 13.3% for the atezolizumab + bevacizumab control arm; duration of response (“DoR”) not yet reached.
Hazard ratio favors the TPST-1120 arm
8-K
EX-99.1
bqezimz
8 Nov 23
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
q1424u6hyqqjz122
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
8-K
EX-10.1
r6daxkej6zse9
17 Apr 19
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
84dc9kie6fql4lz6l
22 Mar 19
Presentation to Lorem Ipsum Dolor May 2018 Corporate Presentation March 2019
5:14pm
8-K
EX-99.1
vu9tdto41ruvbo9u
7 Jan 19
Presentation to Lorem Ipsum Dolor May 2018 Corporate Presentation January 2019
8:54am
10-12G/A
EX-10.23
4kx99ss9y tuxuz9akt
17 May 12
Registration of securities (amended)
12:00am
- Prev
- 1
- Next